Magenta MedicalAnnounced the completion of a new round of $105 million financing, led by Novo Holdings, with participation from Viking Global Investors, RA Capital Management, OrbiMed, New Enterprise Associates (NEA), JVC Investment Partners, and ALIVE-Israel HealthTech Fund. This round of financing mainlyUsed to advanceMagenta ElevateClinical research, and ensureMagenta ElevateFDA Approval Obtained (ApplicablePatients undergoing high-risk percutaneous coronary intervention (HR-PCI).
Investor Evaluation
"Magenta's technology is at the forefront of innovation in the MCS field, with the potential to significantly improve outcomes for patients with severe cardiovascular diseases. We look forward to supporting the Magenta team in providing better care for more patients in need of mechanical circulatory support."
---Eric Snyder Novo Holdings US Venture PartnerExecutive Evaluation
"Magenta is delighted to bring these outstanding medical technology investors on board for its mission to revolutionize the MCS field. We are fortunate to have gathered a group of world-class investors, alongside our existing partners, who possess the resources and expertise to help Magenta navigate regulatory approvals and achieve commercial growth."
---David Israeli, CEO of Magenta Medical
Mechanical Circulatory Support (MCS) is one of the fastest-growing markets in interventional cardiology. To this end, Johnson & Johnson spent $16.6 billion acquiring Abiomed two years ago.Abiomed Directly Propels Johnson & Johnson Back to the Top Four in the Cardiovascular Field; Wait Until the End of This YearJohnson & JohnsonThe ranking will further improve. According to Johnson & Johnson's announcement of this year's second-quarter sales, Abiomed's sales reached 379 million U.S. dollars, a year-on-year increase of 14.5%, accounting for over 20% of Johnson & Johnson's cardiovascular sector, and this proportion is expected to further increase in the future.As Impella sales further increase, the market is becoming more optimistic about interventional cardiac pumps. However, interventional cardiac pumps are not easy to develop, even for those who have been operating in this field for over a decade.Abiomed (Johnson & Johnson) will also encounter various issues. Since last year, Johnson & Johnson has been facing problems due toImpella has been recalled multiple times, but fortunately, it's not a major issue.The Impella series of heart pumps continues to rise.For "Newcomers"Magenta MedicalNeed to face more difficulties, but it overcomes them through technology.Overcome Already ListedImpella Series Heart Pumps FaceSignificant limitations, thereby addressing the technical difficulties it faces. ThereforeMagenta MedicalAlso gained the favor of capital.
Magenta ElevateIt is a self-expanding interventional cardiac pump designed to provide temporary mechanical circulatory support to the left ventricle (LV) in high-risk percutaneous coronary intervention (HR-PCI) and cardiogenic shock (CS) inpatients.
Magenta ElevateThrough a commercially available 10Fr guiding sheath, it reaches the left ventricle under the guidance of a 0.018" guidewire. Once placed in the left ventricle, the self-expanding pump head detaches from the sheath, expanding from 9Fr to 30Fr.Magenta ElevateCan deliver an average flow rate of >5L/min to the ascending aorta (with peak flow exceeding 7L/min).
Magenta ElevateThe reason for achieving a small size and large flow is due to its unique self-expanding impeller and pump head design. The self-expanding impeller consists of a thin memory alloy frame and a soft material forming the main body of the blades. When an axial force is applied during compression, the impeller elongates and its diameter decreases. When it needs to be deployed and re-expanded, the removal of the axial force allows the impeller to return to its original working position. The size ratio of the self-expanding impeller before and after compression is as high as 3.5:1, which is a very large expansion ratio.
It can be saidMagenta ElevateRegardless of size or blood flow pumping capacitySuperior toImpella ECP。
Magenta MedicalMagenta Medical is an innovative medical device company dedicated to developing minimally invasive cardiac pumps, aiming to provide native heart support during episodes of acute dysfunction that could lead to dangerously low blood pressure and impaired perfusion of vital organs.
